Advertisement
News
Advertisement

Mitsubishi Electric Begins Testing New Proton Therapy Technology

Tue, 05/14/2013 - 9:30pm
The Associated Press

TOKYO--(BUSINESS WIRE)--May 14, 2013--Mitsubishi Electric Corporation (TOKYO:6503) announced today that it has completed the construction of a new proton therapy system for cancer treatment at its Energy Systems Center in Kobe, Hyogo Prefecture. The company has started testing of the new technology including a high dose-rate beam delivery system which reduces the irradiation time to one fourth of the current level.

Mitsubishi Electric plans to perform the quality verification testing of this new system in collaboration with clinical institutions, and also utilize the preferred status granted as a member of the Kansai Innovation Comprehensive Global Strategic Special Zone in order to obtain early approval as a medical device.

Key Technologies to be Tested 1) High dose-rate beam delivery system The new beam delivery system is intended to increase the maximum dose rate from 5Gy/min to about 15 to 20Gy/min at all depths, reducing the time to irradiate a tumor by as much as a factor of four over the current level. The shorter irradiation time provides a more comfortable setting for the patient.

2) High-accuracy pencil beam scanning technology The new system increases the scanning speed five fold from 20mm/ms to 100mm/ms. At the same time the spot size is reduced in half from 10mm to 5mm. This means that the proton beam can be delivered more accurately more efficiently to complicated tumor volumes.

3) Universal nozzle for efficient operation The treatment system supports a new nozzle capable of both pencil beam scanning and broad beam treatment. In pencil beam scanning, a finely focused particle beam is magnetically scanned across the tumor, tracing out the three-dimensional tumor volume. In broad beam treatment, the particle beam is spread out to create a uniform field. Using collimators, the treatment field is cut out from this uniform field according to the tumor shape. The nozzle is capable of quickly switching between the two modes of treatment.

Mitsubishi Electric has 50 years of experience and expertise in the fields of radiation therapy and accelerator systems, which the company combined to develop the particle therapy system. In 2002, Mitsubishi Electric obtained approval from the Ministry of Health, Labour and Welfare in Japan to manufacture and sell the proton therapy systems. In 2005, the company became the first manufacturer in the world to obtain approval for the carbon/proton-type therapy systems. In March 2010, approval was obtained for the "Compact Carbon-Type Particle Therapy System," which was developed on the basis of the research work led by the National Institute of Radiological Sciences. To date, the above three types of systems have been installed at a total of eight facilities in Japan.

Mitsubishi Electric will continue to develop new technologies for the advancement of particle therapy, and in collaboration with clinical institutions, provide treatment systems that are safe and easy to use.

About Mitsubishi Electric
With over 90 years of experience in providing reliable, high-quality products, Mitsubishi Electric Corporation (TOKYO:6503) is a recognized world leader in the manufacture, marketing and sales of electrical and electronic equipment used in information processing and communications, space development and satellite communications, consumer electronics, industrial technology, energy, transportation and building equipment. Embracing the spirit of its corporate statement, Changes for the Better, and its environmental statement, Eco Changes, Mitsubishi Electric endeavors to be a global, leading green company, enriching society with technology. The company recorded consolidated group sales of 3,567.1 billion yen (US$ 37.9 billion*) in the fiscal year ended March 31, 2013. For more information visit http://www.MitsubishiElectric.com

*At an exchange rate of 94 yen to the US dollar, the rate given by the Tokyo Foreign Exchange Market on March 31, 2013

Topics

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading